文献速递肿瘤 PET/CT甲状腺核医学放射性药物与辐射防护

新型CCK2R靶向化合物68Ga-DOTA-CCK-66用于甲状腺髓样癌显像的生物分布与辐射剂量学

Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid Cancer.
PubMed 文献 · Clin Nucl Med · 2024-08-02

研究纳入6例甲状腺髓样癌患者,静脉注射169±19 MBq的68Ga-DOTA-CCK-66后行全身PET/CT,计算器官吸收剂量与有效剂量。注射标准活度150 MBq时有效剂量为4.5±0.9 mSv,最高吸收剂量位于膀胱壁(40 mGy)和胃(15 mGy)。6例中2例检出CCK2R表达肿瘤病灶。

要点

  • 注射150 MBq的68Ga-DOTA-CCK-66有效剂量为4.5±0.9 mSv。
  • 最高器官吸收剂量为膀胱壁40 mGy和胃15 mGy。
  • 6例中2例检出CCK2R表达肿瘤病灶,包括淋巴结、骨和肝转移。

核心结论

  • 68Ga-DOTA-CCK-66剂量学表现良好,除胃的生理性受体表达外未见其他相关示踪剂聚集。

研究设计与样本

  • 6例有甲状腺髓样癌病史的患者静脉注射169±19 MBq的68Ga-DOTA-CCK-66,于注射后10分钟、1小时、2小时和4小时行全身PET/CT,采用OLINDA/EXM计算平均器官吸收剂量和有效剂量。

主要发现

  • 注射标准活度150 MBq的68Ga-DOTA-CCK-66有效剂量为4.5±0.9 mSv。
  • 最高吸收器官剂量为膀胱壁40 mGy和胃15 mGy,其次为肾脏6 mGy,肝脏和脾脏各3 mGy。
  • 6例患者中2例检出CCK2R表达肿瘤病灶,包括淋巴结、骨和肝转移。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT: Cholecystokinin 2 receptor (CCK 2 R) is a promising target for imaging and treatment of medullary thyroid cancer due to its overexpression in over 90% of tumor cells. 68 Ga-DOTA-CCK-66 is a recently introduced PET tracer selective for CCK 2 R, which has shown favorable pharmacokinetics in vivo in preclinical experiments. In order to further investigate safety and suitability of this tracer in the human setting, whole-body distribution and radiation dosimetry were evaluated. PATIENTS AND METHODS: Six patients with a history of medullary thyroid cancer were injected intravenously with 169 ± 19 MBq of 68 Ga-DOTA-CCK-66. Whole-body PET/CT scans were acquired at 10 minutes, 1 hour, 2 hours, and 4 hours after tracer injection. Time-activity curves per organ were determined, and mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM. RESULTS: Injection of a standard activity of 150 MBq of 68 Ga-DOTA-CCK-66 results in an effective dose of 4.5 ± 0.9 mSv. The highest absorbed organ doses were observed in the urinary bladder wall (40 mGy) and the stomach (15 mGy), followed by the kidneys (6 mGy), as well as the liver and the spleen (3 mGy each). CCK 2 R-expressing tumor manifestations could be detected in 2 of the 6 patients, including lymph node, bone, and liver metastases. CONCLUSIONS: 68 Ga-DOTA-CCK-66 exhibits a favorable dosimetry. Beyond physiologic receptor expression of the stomach, no other relevant tracer accumulation could be observed, rendering this organ at risk in case of subsequent radioligand therapy using 177 Lu-DOTA-CCK-66.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Viering O, Rinscheid A, Holzleitner N, et al. Biodistribution and Radiation Dosimetry for 68 Ga-DOTA-CCK-66, a Novel CCK 2 R-Targeting Compound for Imaging of Medullary Thyroid Cancer. Clin Nucl Med. 2024. PMID: 39093043. doi:10.1097/RLU.0000000000005355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。